The Role of MicroRNAs in Autoimmune Diseases with Skin Involvement

Scandinavian Journal of Immunology

Volumn 81, Issue 3, 2015, Pages 153-165

  Deng, X ^a   Su, Y ^a   Wu, H ^a   Wu, R ^a   Zhang, P ^a   Dai, Y ^b   Chan, T M ^c   Zhao, M ^a   Lu, Q ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SHENZHEN PEOPLE'S HOSPITAL   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 125A; MICRORNA 125B; MICRORNA 142 3P; MICRORNA 142 5P; MICRORNA 145; MICRORNA 146A; MICRORNA 155; MICRORNA 196A; MICRORNA 203; MICRORNA 206; MICRORNA 21; MICRORNA 223; MICRORNA 29; UNCLASSIFIED DRUG; GENETIC MARKER;

ARTICLE; AUTOIMMUNE SKIN DISEASE; AUTOIMMUNITY; BASIC RESEARCH; BEHCET DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; GENE TARGETING; HUMAN; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PSORIASIS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; AUTOIMMUNE DISEASE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; SKIN DISEASE;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; BEHCET SYNDROME; DERMATOMYOSITIS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICRORNAS; PSORIASIS; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 84923228631     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12261     Document Type: Article

References (93)

1. Selmi C, Lu Q, Humble MC. Heritability versus the role of the environment in autoimmunity. J Autoimmun 2012;39:249-52.
2. Miller FW, Pollard KM, Parks CG et al. Criteria for environmentally associated autoimmune diseases. J Autoimmun 2012;39:253-8.
3. Bird A. Perceptions of epigenetics. Nature 2007;447:396-8.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
5. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009;32:189-94.
6. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111-22.
7. Cevec M, Thibaudeau C, Plavec J. NMR structure of the let-7 miRNA interacting with the site LCS1 of lin-41 mRNA from Caenorhabditis elegans. Nucleic Acids Res 2010;38:7814-21.
8. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9:102-14.
9. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126-39.
10. Mello CC, Conte D Jr. Revealing the world of RNA interference. Nature 2004;431:338-42.
11. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012;19:586-93.
12. Nilsen TW. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet 2007;23:243-9.
13. Singh RP, Massachi I, Manickavel S et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev 2013;12:1160-5.
14. Hu R, O'Connell RM. MicroRNA control in the development of systemic autoimmunity. Arthritis Res Ther 2013;15:202.
15. Yu D, Tan AH, Hu X et al. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007;450:299-303.
16. Liston A, Lu LF, O'Carroll D, Tarakhovsky A, Rudensky AY. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med 2008;205:1993-2004.
17. Zhou X, Jeker LT, Fife BT et al. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008;205:1983-91.
18. Divekar AA, Dubey S, Gangalum PR, Singh RR. Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol 2011;186:924-30.
19. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013;39:949-62.
20. Iborra M, Bernuzzi F, Invernizzi P, Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev 2012;11:305-14.
21. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
22. Tang Y, Luo X, Cui H et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009;60:1065-75.
23. Zhao S, Wang Y, Liang Y et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 2011;63:1376-86.
24. Stagakis E, Bertsias G, Verginis P et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011;70:1496-506.
25. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103:12481-6.
26. Garcin G, Bordat Y, Chuchana P et al. Differential activity of type I interferon subtypes for dendritic cell differentiation. PLoS One 2013;8:e58465.
27. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009;1792:497-505.
28. Wen Z, Xu L, Chen X et al. Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol 2013;190:5411-22.
29. Thai TH, Patterson HC, Pham DH et al. Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse. Proc Natl Acad Sci USA 2013;110:20194-9.
30. Lashine YA, Salah S, Aboelenein HR, Abdelaziz AI (2014) Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus doi: 10.1177/0961203314552117. [Epub ahead of print].
31. Garchow BG, Bartulos Encinas O, Leung YT et al. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med 2011;3:605-15.
32. Pan W, Zhu S, Yuan M et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010;184:6773-81.
33. Tang ZM, Fang M, Wang JP et al. (2014) Clinical relevance of plasma miR-21 in new-onset systemic lupus erythematosus patients. J Clin Lab Anal 2014;28: 446-451.
34. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 2007;104:17719-24.
35. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-91.
36. Ding S, Liang Y, Zhao M et al. Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus. Arthritis Rheum 2012;64:2953-63.
37. Zhao X, Tang Y, Qu B et al. MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum 2010;62:3425-35.
38. Moore KJ, Wada T, Barbee SD, Kelley VR. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice. Kidney Int 1998;53:1631-41.
39. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008;14:872-7.
40. Qin H, Zhu X, Liang J et al. MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1. J Dermatol Sci 2013;69:61-7.
41. Ha TY. MicroRNAs in human diseases: from cancer to cardiovascular disease. Immune Netw 2011;11:135-54.
42. Weigle N, McBane S. Psoriasis. Am Fam Physician 2013;87:626-33.
43. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54:S67-80.
44. Joyce CE, Zhou X, Xia J et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 2011;20:4025-40.
45. Sonkoly E, Wei T, Janson PC et al. (2007) MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS ONE 2: e610.
46. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol 2010;71:382-5.
47. Ichihara A, Jinnin M, Oyama R et al. Increased serum levels of miR-1266 in patients with psoriasis vulgaris. Eur J Dermatol 2012;22:68-71.
48. Xu N, Meisgen F, Butler LM et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. J Immunol 2013;190:678-88.
49. Meisgen F, Xu N, Wei T et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol 2012;21:312-4.
50. Zhao M, Wang LT, Liang GP et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4 T cells of psoriasis vulgaris. Clin Immunol 2013;150:22-30.
51. Guo S, Zhang W, Wei C et al. Serum and skin levels of miR-369-3p in patients with psoriasis and their correlation with disease severity. Eur J Dermatol 2013;23:608-13.
52. Xu N, Brodin P, Wei T et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol 2011;131:1521-9.
53. Zibert JR, Lovendorf MB, Litman T et al. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010;58:177-85.
54. Primo MN, Bak RO, Schibler B, Mikkelsen JG. Regulation of pro-inflammatory cytokines TNFalpha and IL24 by microRNA-203 in primary keratinocytes. Cytokine 2012;60:741-8.
55. Wei T, Xu N, Meisgen F et al. (2013) Interleukin-8 is regulated by miR-203 at the posttranscriptional level in primary human keratinocytes. Eur J Dermatol doi:10.1684/ejd.2013.1997 Apr 19. [Epub ahead of print].
56. Sonkoly E, Wei T, Pavez Lorie E et al. Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol 2010;130:124-34.
57. Xia P, Fang X, Zhang ZH et al. Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol Lett 2012;148:151-62.
58. Nakasa T, Miyaki S, Okubo A et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008;58:1284-92.
59. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
60. Boele J, Persson H, Shin JW et al. PAPD5-mediated 3′ adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease. Proc Natl Acad Sci USA 2014;111:11467-72.
61. Guinea-Viniegra J, Jimenez M, Schonthaler HB et al. (2014) Targeting miR-21 to treat psoriasis. Sci Transl Med 6:221-225.
62. Tili E, Michaille JJ, Cimino A et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007;179:5082-9.
63. Pattanaik D, Brown M, Postlethwaite AE. Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res 2011;4:105-25.
64. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
65. Luo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun 2013;41:161-7.
66. Zhu H, Luo H, Zuo X. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. Exp Mol Med 2013;45:e41.
67. Zhu H, Li Y, Qu S et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012;32:514-22.
68. Li H, Yang R, Fan X et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int 2012;32:307-13.
69. Peng WJ, Tao JH, Mei B et al. MicroRNA-29: a potential therapeutic target for systemic sclerosis. Expert Opin Ther Targets 2012;16:875-9.
70. Maurer B, Stanczyk J, Jungel A et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010;62:1733-43.
71. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 2007;9:136-43.
72. Honda N, Jinnin M, Kajihara I et al. TGF-beta-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 2012;188:3323-31.
73. Nakashima T, Jinnin M, Yamane K et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012;188:3573-83.
74. Sing T, Jinnin M, Yamane K et al. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology (Oxford) 2012;51:1550-6.
75. Kajihara I, Jinnin M, Yamane K et al. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am J Pathol 2012;180:703-14.
76. Honda N, Jinnin M, Kira-Etoh T, et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin beta3. Am J Pathol 2013;182:206-16.
77. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-98.
78. Nagaraju K, Lundberg IE (2011) Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin North Am 37: 159-71, v.
79. Tang X, Tian X, Zhang Y et al. Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis. Clin Dev Immunol 2013;2013:345347.
80. Inoue K, Jinnin M, Yamane K et al. Down-regulation of miR-223 contributes to the formation of Gottron's papules in dermatomyositis via the induction of PKCvarepsilon. Eur J Dermatol 2013;23:160-7.
81. Oshikawa Y, Jinnin M, Makino T et al. Decreased miR-7 expression in the skin and sera of patients with dermatomyositis. Acta Derm Venereol 2013;93:273-6.
82. Kim E, Cook-Mills J, Morgan G, Sredni ST, Pachman LM. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum 2012;64:3809-17.
83. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet's disease. Autoimmun Rev 2012;11:687-98.
84. Ishida W, Fukuda K, Higuchi T et al. Dynamic changes of microRNAs in the eye during the development of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011;52:611-7.
85. Zhou Q, Hou S, Liang L et al. MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome. Ann Rheum Dis 2014;73:170-6.
86. Zhou Q, Xiao X, Wang C et al. Decreased microRNA-155 expression in ocular Behcet's disease but not in Vogt Koyanagi Harada syndrome. Invest Ophthalmol Vis Sci 2012;53:5665-74.
87. Alevizos I, Illei GG. MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 2010;6:391-8.
88. Wang G, Tam LS, Li EK et al. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 2011;20:493-500.
89. Wang G, Tam LS, Li EK et al. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 2010;37:2516-22.
90. Carlsen AL, Schetter AJ, Nielsen CT et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum 2013;65:1324-34.
91. Wang H, Peng W, Ouyang X, Li W, Dai Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res 2012;160:198-206.
92. Kawashita Y, Jinnin M, Makino T et al. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci 2011;61:67-9.
93. Haussecker D, Kay MA. miR-122 continues to blaze the trail for microRNA therapeutics. Mol Ther 2010;18:240-2.